archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Announces Changes to the Board
    Australia to become Executive Director of the Garvan Institute of Medical Research a position that he will be stepping down from at the end of 2011 and developed it as one of Australia s premier Medical Institutes Professor Shine was formerly Chairman of the National Health and Medical Research Council and a member of the Prime Minister s Science Engineering and Innovation Council In November 2010 he was awarded the Prime Minister s Prize for Science Professor Shine has extensive Board and governance experience and is well placed to guide CSL s strategic future Miss Alexander has been a Director of the Company since July 1991 and has been Chairman since October 2006 Prior to becoming the Chairman of CSL she was the Chairman of CSL s Audit and Risk Committee Miss Alexander played a key role in CSL s highly successful public listing and has been a constant champion of the Company s international expansion plans Her financial leadership and strong commitment to corporate governance has helped transform CSL from a domestic biologics manufacturer to a global speciality biopharmaceutical company Mr Simpson has been a director of the Company since September 2006 and has served as a member and Chairman of both the Company s Audit and Risk Management Committee and the Human Resources and Remuneration Committee CSL s Chairman elect Professor John Shine said I am very proud to be taking over as Chairman from Elizabeth after the Annual General Meeting She has made an extraordinary contribution to CSL over many years and leaves the Company well positioned for the future I would also like to recognise and thank David for his commitment and contribution during his time as a Director CSL today also announced that Mr Bruce Brook has been appointed a Director of the Company effective

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255927066426/prdetail.htm (2014-01-05)
    Open archived version from archive


  • CSL Limited today announced CSL announces A$900m share buy-back
    return on equity said Ms Alexander At yesterday s closing price of A 30 21 a A 900 million buy back represents approximately 30 million CSL shares or around 6 of CSL s issued share capital It is CSL s fifth share buy back with the Company returning almost 20 of its shares to shareholders since 2005 Ms Alexander also told shareholders today that the Company was well progressed in achieving the capital management initiatives foreshadowed earlier this year I am pleased to announce that CSL is now close to finalising negotiations with its banks for new lines of credit for up to the equivalent of A 750 million CSL has also raised US 750 million through a US private placement subject to final documentation and closing The placement was well received by investors and was significantly oversubscribed The new credit facilities and debt placement will significantly lengthen CSL s debt profile at very attractive long term interest rates and will enable CSL to move towards its objective of maintaining a leverage ratio Net Debt to EBIDTA within the range of 0 7 to 1 2 This is an excellent outcome given the volatility of the financial markets and is

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255927497719/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    news 1196562741382 prdetail htm News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1196562810146 prdetail htm News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1196562810412 prdetail htm News Archive Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1196562810761 prdetail htm CSL Limited responds to FTC announcement Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1242703908232 prdetail htm CSL Receives USD180 million approximately AUD230 million Order Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1242703933086 prdetail htm CSL reaffirms its commitment to supply Australia with Novel Influenza Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1242703934562 prdetail htm CSL Backs Key Training Program for Health and Medical Sciences Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1247066858057 prdetail htm Vaccine delivered on time

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=170&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • Contact Us - Australia
    Careers Newsroom Contact CSL Home Contact Us Australia Business in Australia For more information about CSL within this region please contact appropriate section CSL Limited Registered Head Office 45 Poplar Rd Parkville Victoria 3052 Australia Phone 61 3 9389 1911 Fax 61 3 9389 1434 Submit General Enquiries CSL Limited Research and Development 45 Poplar Road Parkville Victoria 3052 Australia Phone 61 3 9389 1911 Fax 61 3 9389 1434 Email cslrd csl com au CSL Behring 189 209 Camp Road Broadmeadows Victoria 3047 Australia Phone 61 3 9246 5200 Fax 61 3 9246 5299 bioCSL 63 Poplar Road Parkville Victoria 3052 Australia Phone 61 3 9389 2000 Fax 61 3 9389 1874 Please contact our medical department for product enquiries or to report an adverse event related to plasma derived therapies pharmaceuticals vaccines or antivenom products Australia 1800 642 865 International 61 3 9389 1932 Customer Service Enquiries for CSL Behring plasma derived therapies Australia 1800 063 892 International 61 3 9246 5231 Email your enquiry Customer Service Enquiries for bioCSL pharmaceutical vaccine and antivenom products Australia 1800 008 275 bioCSL Immunohaematology 63 Poplar Rd Parkville Victoria 3052 Australia Phone 61 3 9389 1919 Fax 61 3 9389 1646

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255927762830/content/1196562656332/content.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    1255923818998 prdetail htm Update on Seasonal Influenza Vaccination of Young Children Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255924331182 prdetail htm CSL Announces New Biotech facility Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255924559119 prdetail htm Update on Seasonal Influenza Vaccination of Children Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255924656041 prdetail htm CSL welcomes historic pandemic agreement Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255926424260 prdetail htm CSL Biotherapies Restricted Supply of BenPen Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255927348167 prdetail htm CSL Biotherapies Response to News Reports on FDA Inspections Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 899 news 1255927385518 prdetail htm CSL Limited announced today that it is partnering with the world Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=180&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • News Archive
    CSL Biotherapies a group member company of CSL and the business unit responsible for developing and manufacturing Panvax In the event of a pandemic CSL will rapidly gear up to manufacturing levels that will ensure all Australians have access to safe effective coverage against avian flu We continue to work collaboratively with the World Health Organisation and with the Australian scientific community to maintain a high level of avian flu preparedness I congratulate CSL and the investigators who worked with them on their development and registration of the Panvax avian influenza vaccine said Australian Minister for Health and Ageing the Hon Nicola Roxon MP This places Australia in an excellent position in terms of its preparedness to manage an avian flu pandemic should one arise and should reassure all Australians CSL is the only vaccine supplier that manufactures influenza vaccines in Australia Through its recent and continuing investment of more than 80m in Fluvax a vaccine against seasonal influenza CSL remains committed to the ongoing provision of influenza vaccines to the Australian community CSL acknowledges the significant contributions made by those Australians who participated in the clinical studies to enable the development of this important vaccine About Panvax Panvax is a vaccine that can be used only when an influenza pandemic has been officially declared by the Australian Government in consultation with the World Health Organisation An influenza pandemic occurs when a new strain of the type A influenza virus emerges that is so different to the seasonal influenza virus strains that it spreads rapidly from person to person In that case it can cause serious illness because very few people have any immunity to the new virus strain CSL has a long history of manufacture of a seasonal influenza virus vaccine Fluvax and applied this knowledge and experience to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1211307236036/prdetail.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 230 news 1255923013047 prdetail htm CSL Appoints New Director Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au 230 news 1255925861380 prdetail htm CSL Limited is a global biotherapy industry leader Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au Jobs and career opportunities at CSL Limited Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au careers CSL Limited is a global biotherapy industry leader Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au home CSL Limited R D for Plasma Therapeutics protein based medicines Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au research development Code of Responsible Business Practice Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au f responsible business practice htm The governance of CSL Limited Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil Canada China Denmark France http www csl com au about governance htm The

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=190&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • Changes to CSL Senior Executive Group
    Behring to Mr Paul Perreault effective 1 July 2011 Mr Perreault is currently a member of the CSL Behring leadership team holding the position Executive Vice President Commercial Operations His career spans 30 years in the Pharmaceutical industry in sales marketing business development and operational roles with both a US and international focus Mr Turner will return to Australia later in the year He will be available on a parttime basis to undertake a range of projects and will continue as an Executive Director Dr Brian McNamee CEO and Managing Director of CSL acknowledged the contribution Mr Turner had made to the growth and success of the CSL Group Peter has been a great contributor to the success story of CSL and he leaves CSL Behring in excellent shape with a strong team excellent growth prospects and a culture which emphasises delivery against challenging goals as well as strong values and ethics he said today Paul represents continuity of our strategy in CSL Behring He brings solid experience and strong leadership qualities to this role I look forward to working closely with him Miss Elizabeth Alexander Chairman CSL Limited in welcoming the opportunity to retain Mr Turner s services as an Executive Director said Over the past 40 years Peter has gained exceptional knowledge of the plasma industry which is extremely valuable to CSL and the Board After contributing to the Company overseas for eleven years through leadership roles in Switzerland and the United States we welcome him back to Melbourne I am very pleased that we have been able to plan successfully to replace Peter in this important role and to have the benefit of his continuing contribution Miss Alexander added Paul is well known to the Board He has been a very effective global leader in Commercial Operations

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562650230/news/1255926123898/prdetail.htm (2014-01-05)
    Open archived version from archive